Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Improving Maternal Nutrition in Matlab (IMNiM)

In-home, Intensive Nutrition Counseling to Improve Gestational Weight Gain in Rural Bangladesh: A Cluster-Randomized Controlled Trial

Background: Maternal undernutrition and inadequate gestational weight gain (GWG) are prevalent in rural communities of low- and middle-income countries (LMICs). In Matlab, Bangladesh, 54% of the women fail to gain adequate weight (>4 kg) in the third trimester. Risks associated with inadequate GWG include giving birth to a small-for-gestational age (SGA) infant, low birth weight (LBW) infant, preterm birth (PTB), etc. Few contemporary studies examined the efficacy of nutrition counseling on GWG improvement in LMICs.

Objectives: The primary objective of this study is to assess whether in-home, intensive nutrition counseling during pregnancy, compared to standard antenatal care, could improve GWG among pregnant women in rural Bangladesh.

Methods: This prospective, two-arm, parallel group, equal allocation, open-label, community-based, cluster-randomized controlled trial will be conducted in the icddr,b service area of Matlab, a rural subdistrict of Bangladesh. Clusters will be randomly allocated 1:1 to the intervention arm in which pregnant women will receive monthly in-home, intensive nutrition counseling or the control arm in which pregnant women will receive standard antenatal care as offered by icddr,b and Govt. facilities. Fixed Site Clinics (FSCs) located at the homes of the community health research workers (CHRWs) will act as clusters. Of the 33 FSCs serving rural areas in the icddr,b service area, 20 will be selected randomly and listed. These 20 clinics will then be randomly allocated 1:1 to either an intervention or control group using a computer-generated random allocation sequence. To fulfil the required sample size, each selected CHRW will enroll 16 consecutive pregnancies. Required sample size is 16 women per cluster i.e. 160 women per arm. Eligible participants will be enrolled upon obtaining their consent by 13 and 6/7 weeks of gestation (first trimester) and followed up to 6 weeks postpartum. Trained health workers will visit the homes of the women in the intervention arm once a month and provide nutrition counseling to the women and her influential family members such as mothers, mothers-in-law and husbands. Both intention-to-treat and per-protocol analyses will be performed.

Outcome measures/variables: Proportion of women with inadequate rate of weight gain in the second and third trimester of pregnancy according to the US Institute of Medicine (IOM) 2009 guidelines is the primary outcome variable.

Descripción general del estudio

Estado

Activo, no reclutando

Tipo de estudio

Intervencionista

Inscripción (Actual)

287

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

      • Chandpur, Bangladesh
        • International Centre for Diarrhoeal Disease Research, Bangladesh

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años a 39 años (Adulto)

Acepta Voluntarios Saludables

Géneros elegibles para el estudio

Femenino

Descripción

Pregnant women permanently residing in the icddr,b service area of Matlab fulfilling the following criteria:

Inclusion Criteria:

  • aged 18-39 years
  • in the first trimester of pregnancy (before 14 weeks of gestation)
  • BMI 16-24.99 kg/m^2 measured on enrollment
  • willing to participate in the study

Exclusion criteria

  • multiple pregnancy (carrying two or more fetuses)
  • threatened abortion, persistent pervaginal bleeding, or cervical incompetence
  • history of three or more consecutive abortions
  • history of gestational diabetes, macrosomia, gestational hypertension, preeclampsia/eclampsia in a prior pregnancy
  • chronic diseases, such as hypertension, heart disease, chronic obstructive pulmonary disease, chronic kidney disease, chronic liver disease, pancreatic diseases, Crohn's disease, ulcerative colitis, diabetes mellitus, thyroid dysfunction, immunological diseases, malignancy or any other diseases which could impede compliance with the study protocol
  • taking medications known to influence fetal growth, such as insulin, thyroid hormones, glucocorticoids
  • known case of serious psychiatric or behavioral disorders, such as schizophrenia, bipolar disorder
  • scored as moderate or worse on enrollment on any one of the subscales of the Depression, Anxiety and Stress Scales-21 (DASS-21)
  • inability to read or write Bengali
  • belonging to moderately or severely food insecure households as measured by the Household Food Insecurity Access Scale (HFIAS)
  • having a plan to move or deliver outside the study area
  • women practicing some form of vegetarianism
  • women belonging to a household from which another woman is already enrolled in the study

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Investigación de servicios de salud
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Intervention
In this arm, pregnant women, along with their influential family members such as mothers, mothers-in-law, and husbands, will receive monthly in-home, intensive nutrition counseling during the prenatal period.
  • Individualized sessions will be conducted by trained health workers following a standard document (counseling booklet)
  • The messages to be provided through the counseling will be contextualized
  • Sessions will start from the early second trimester and repeat monthly until 36 weeks of gestation
  • Counseling sessions will be conducted at the participant's place
  • Sessions will involve influential family members such as the husband, mother-in-law, mother, and the household head along with the pregnant women
  • Women will receive personalized feedback on their dietary intake pattern (dietary diversity) and the rate of weight gain in each session
  • Sessions will be tailored according to each participant's need and progress
Sin intervención: Control
Pregnant women in this arm will receive standard antenatal care.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
proportion of women with inadequate rate of weight gain in the second and third trimester of pregnancy according to IOM 2009 guidelines
Periodo de tiempo: Pre-delivery
Pregnancy trimesters are defined as follows: 1st trimester (0 weeks - 13+6 weeks), 2nd trimester (14 completed weeks - 27+6 weeks), and 3rd trimester (28 completed weeks - childbirth). Rate of weight gain between two time points (trimesters) will be calculated by subtracting the weight measured at the first time point from the weight measured at the second time point and dividing the derived value by the difference in weeks between the two time points.
Pre-delivery

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
total gestational weight gain (kg)
Periodo de tiempo: pre-delivery
pre-delivery
rate of weight gain during the 2nd and 3rd trimester (kg/week)
Periodo de tiempo: pre-delivery
pre-delivery
proportion of women with inadequate total GWG according to IOM criteria
Periodo de tiempo: pre-delivery
pre-delivery
proportion of women with inadequate total GWG according to local criteria
Periodo de tiempo: pre-delivery
pre-delivery
proportion of women with inadequate third trimester weight gain according to local criteria
Periodo de tiempo: pre-delivery
pre-delivery
proportion of preterm births
Periodo de tiempo: at delivery
childbirth before 37 completed weeks
at delivery
maternal mid-upper arm circumference (MUAC) (mm)
Periodo de tiempo: baseline, 36 weeks of gestation, at delivery and 6 weeks post-partum
baseline, 36 weeks of gestation, at delivery and 6 weeks post-partum
maternal weight (kg)
Periodo de tiempo: baseline, 36 weeks of gestation, pre-delivery, at delivery and 6 weeks post-partum
baseline, 36 weeks of gestation, pre-delivery, at delivery and 6 weeks post-partum
maternal body mass index (BMI) (kg/m^2)
Periodo de tiempo: baseline, 36 weeks of gestation, pre-delivery, at delivery and 6 weeks post-partum
weight and height (at baseline) will be combined to report BMI
baseline, 36 weeks of gestation, pre-delivery, at delivery and 6 weeks post-partum
infant weight (g)
Periodo de tiempo: at birth (delivery) and after 4 weeks
at birth (delivery) and after 4 weeks
infant length (cm)
Periodo de tiempo: at birth (delivery) and after 4 weeks
at birth (delivery) and after 4 weeks
infant head circumference (cm)
Periodo de tiempo: at birth (delivery) and after 4 weeks
at birth (delivery) and after 4 weeks
proportion of low birth weight (< 2500 g) infants
Periodo de tiempo: at birth (delivery)
at birth (delivery)
proportion of small for gestational age (<10th percentile) infants according to Intergrowth-21st standards
Periodo de tiempo: at birth (delivery)
at birth (delivery)
proportion of women with pregnancy complications e.g. anemia, preeclampsia
Periodo de tiempo: at delivery
at delivery
proportion of women with obstetric complications e.g. induction of labor, caesarean section
Periodo de tiempo: at delivery
at delivery
newborn Apgar score
Periodo de tiempo: at birth (delivery)
at birth (delivery)
proportion of infants developing morbidity
Periodo de tiempo: 4 weeks after birth
4 weeks after birth
proportion of infant mortality
Periodo de tiempo: 4 weeks after birth
4 weeks after birth
dietary diversity score according to the "Guidelines for Measuring Household and Individual Dietary Diversity"
Periodo de tiempo: baseline, 36 weeks of gestation and 6 weeks post-partum
score range: 0-9; higher scores indicate a better outcome
baseline, 36 weeks of gestation and 6 weeks post-partum
dietary diversity score according to the "Minimum Dietary Diversity for Women: A Guide to Measurement"
Periodo de tiempo: baseline, 36 weeks of gestation and 6 weeks post-partum
score range: 0-10; higher scores indicate a better outcome
baseline, 36 weeks of gestation and 6 weeks post-partum
proportion of women with inadequate dietary diversity accroding to the "Minimum Dietary Diversity for Women: A Guide to Measurement"
Periodo de tiempo: baseline, 36 weeks of gestation and 6 weeks post-partum
score range: 0-10; <5 indicates inadequate dietary diversity
baseline, 36 weeks of gestation and 6 weeks post-partum
energy consumption (kcal)
Periodo de tiempo: baseline, 36 weeks of gestation and 6 weeks post-partum
baseline, 36 weeks of gestation and 6 weeks post-partum
protein consumption (g)
Periodo de tiempo: baseline, 36 weeks of gestation and 6 weeks post-partum
baseline, 36 weeks of gestation and 6 weeks post-partum
proportion of women with symptoms of depression as measured by Depression, Anxiety, and Stress Scales-21 (DASS-21) scales
Periodo de tiempo: baseline, 36 weeks of gestation and 6 weeks post-partum
DASS-21 is a validated, widely used, standardized self-report scale with 7 items in each subscale category of Depression, Anxiety, and Stress symptoms. Responses are scored on a 4-point Likert scale ranging from 0 (did not apply to me at all) to 3 (applied to me very much/most of the time), with higher scores indicating higher levels of depression, anxiety or stress.
baseline, 36 weeks of gestation and 6 weeks post-partum
proportion of women with symptoms of anxiety as measured by Depression, Anxiety, and Stress Scales-21 (DASS-21) scales
Periodo de tiempo: baseline, 36 weeks of gestation and 6 weeks post-partum
DASS-21 is a validated, widely used, standardized self-report scale with 7 items in each subscale category of Depression, Anxiety, and Stress symptoms. Responses are scored on a 4-point Likert scale ranging from 0 (did not apply to me at all) to 3 (applied to me very much/most of the time), with higher scores indicating higher levels of depression, anxiety or stress.
baseline, 36 weeks of gestation and 6 weeks post-partum
proportion of women with symptoms of stress as measured by Depression, Anxiety, and Stress Scales-21 (DASS-21) scales
Periodo de tiempo: baseline, 36 weeks of gestation and 6 weeks post-partum
DASS-21 is a validated, widely used, standardized self-report scale with 7 items in each subscale category of Depression, Anxiety, and Stress symptoms. Responses are scored on a 4-point Likert scale ranging from 0 (did not apply to me at all) to 3 (applied to me very much/most of the time), with higher scores indicating higher levels of depression, anxiety or stress.
baseline, 36 weeks of gestation and 6 weeks post-partum
healthcare seeking and services utilization e.g. number of prenatal visits
Periodo de tiempo: at delivery
at delivery

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Investigadores

  • Investigador principal: S. M. Tafsir Hasan, MBBS, MS, Nutrition and Clinical Services Division, icddr,b

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

15 de enero de 2020

Finalización primaria (Anticipado)

30 de septiembre de 2021

Finalización del estudio (Anticipado)

31 de octubre de 2021

Fechas de registro del estudio

Enviado por primera vez

28 de diciembre de 2019

Primero enviado que cumplió con los criterios de control de calidad

27 de abril de 2021

Publicado por primera vez (Actual)

3 de mayo de 2021

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

3 de mayo de 2021

Última actualización enviada que cumplió con los criterios de control de calidad

27 de abril de 2021

Última verificación

1 de abril de 2021

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir